Matthieu Roulleaux Dugage

@LAGovJeffLandry @realDonaldTrump Greenland belong to greelanders. Greenland is european territory.

Un grand merci à l’@IFCTlung et son conseil scientifique pour ce prix et leur soutien à notre projet. AUREMESO permettra, je l’espère, l’identification de nouvelles cibles et de nouveaux biomarqueurs pour les patients traités pour un mésothéliome ! @GustaveRoussy

🚀 Kicking off the 2nd #CCETRYTRAC face-to-face meeting — this time at @NCT_HD, Germany! 💡 Excited for three days of learning, exchange, and networking. @VHIO @DKFZ @IstTumori @karolinskainst @NKI_nl @GustaveRoussy @CRUKCamCentre

Up to 50% of patients with metastatic cancer develop lung metastases, linked to poor prognosis and impaired quality of life. Our Nature Reviews Disease Primers article unpacks biology, diagnosis & treatment strategies. @LodovicaZullo @GustaveRoussy nature.com/articles/s4157…

Comparison of EGFR NSCLC transformed to #SCLC vs de novo SCLC @LungCaJournal. OS shorter with transformed SCLC esp with high neuroendocrine marker expression. In transformed SCLC, OS with chemo-immunotherapy superior to chemo +/- TKI (15.4m vs 8.5m). lungcancerjournal.info/article/S0169-…

New drugs @ASCO2025 @GustaveRoussy

Without its international students, Harvard is not Harvard. hrvd.me/IntStudents25t

@GerardAraud Indépendamment de l’épineuse question du salaire de ces chercheurs, il faut surtout financer leurs projets, et avoir les infrastructures pour les accueillir. Il faudrait un investissement massif, probablement non réaliste.

En tant qu’ambassadeur aux États Unis, je n’ai cessé d?y rencontrer des chercheurs français qui auraient préféré revenir dans leur pays mais qui se heurtaient aux conditions qu’on leur y offrait en termes de rémunération et de laboratoire. Ce genre de déclaration m’effare.

IL-6R blockade to uncouple toxicité ans efficace in ICB-treated patients ? Our editorial @Annals_Oncology 👇 Thank you to coauthors !!

New article in press: Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. @peters_solange doi.org/10.1016/j.anno…

New drugs ESMO2024

First Cellular Therapy approved for a solid tumor! In synovial sarcoma an orphan tumor! Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Thrilled to announce the publication of our latest research in Nature Immunology. Joining forces with 20 laboratories in Europe and USA, we identified the three prominent NK cell subsets in human: NK1, NK2, and NK3: rdcu.be/dMuAs

Wonderful results, once again highlighting the immunosuppressive effects of liver metastases in patients treated with immunotherapy (impressive waterfall plot)

Anyone still think we should not be using immune checkpoint inhibitors before surgery? Or that use of adjuvant ICI only is as good as neoadjuvant ICI? Phase 3 trial in resectable melanoma now in @NEJM concurrent with plenary by @ProfCUBlankNKI #ASCO24 nejm.org/doi/full/10.10…

It had me at "the normal intact adult pancreas harbours hundreds of pancreatic intraepithelial neoplasias (PanINs), almost all with oncogenic KRAS hotspot mutations" Spatial omics of pancreatic cancer nature.com/articles/s4158… @Nature @lauradelongwood @deniswirtz @AshleyKiemen

@RobertoFerrara_ @AIRC_it @MyUniSR Wonderful design 👏 Great to see resistance biomarkers prospectively investigated & LIPI included as a stratification factor.

Super happy for AIRC Next Generation Clinician Scientist: 1.5 million euros! Chemo+ICI vs ICI in PD-L1>50% NSCLC pts selected for high-risk of hyperprogression according to neutrophils phenotype. 27 institutions across Europe and open to recruit more centers @AIRC_it @MyUniSR

Our most complex biologic system—immunity—is reviewed in 3 new @CellCellPress papers, open-access Adaptive cell.com/cell/fulltext/… Innate cell.com/cell/fulltext/… New insights cell.com/cell/fulltext/… @RMedzhitov

ICI-chemotherapy did not improve survival compared with ICI alone in older adults with previously untreated advanced NSCLC, but increased the incidence of grade 3 and higher immune-related adverse events. ja.ma/3UnrP7Q

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in @CD_AACR today rb.gy/q484j9 Tweetorial👇